Axsome stock tumbled Tuesday after Axsome Therapeutics issued mixed results for its drug, Sunosi, in ADHD treatment.

Axsome Therapeutics (NASDAQ:AXSM) announced Tuesday that solriamfetol, its experimental therapy for attention deficit ...

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its target price boosted by stock analysts at Mizuho from $212.00 to ...

Mizuho analyst Graig Suvannavejh raised the firm’s price target on Axsome Therapeutics (AXSM) to $216 from $212 and keeps an Outperform rating ...

Taking a gamble by purchasing the rights to an underperforming narcolepsy drug may soon begin paying dividends for Axsome ...

The German firm licensed a PRMT5 inhibitor that’s now in Phase 1 testing. Elsewhere, GSK is testing an intriguing hypothesis ...

March 25 (Reuters) - Axsome Therapeutics' (AXSM.O), opens new tab experimental drug to treat attention deficit hyperactivity disorder (ADHD) helped improve symptoms of the developmental disorder ...

The randomised trial saw over half of patients dosed with Sunosi were able to achieve clinical response to the therapy ...

Explore Axsome Therapeutics stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for AXSM. Axsome's solriamfetol met primary and key secondary endpoints in a ...

HighTower Advisors LLC purchased a new position in Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) during the fourth ...

The latest price target for Axsome Therapeutics (NASDAQ:AXSM) was reported by Mizuho on March 27, 2025. The analyst firm set a price target for $216.00 expecting AXSM to rise to within 12 months ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Roche Holding AG (RHHVF – Research Report), ...